# The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers

> **NCT02654522** · PHASE1 · COMPLETED · sponsor: **Steve Yoelin M.D. Medical Associates, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Dermal Filler

## Interventions

- **DRUG:** Hylenex

## Key facts

- **NCT ID:** NCT02654522
- **Lead sponsor:** Steve Yoelin M.D. Medical Associates, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02654522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02654522, "The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02654522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*